Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Generic-Drug Price Fixing: Is It Happening?

Philip Seo, MD, MHS  |  Issue: May 2018  |  May 17, 2018

It started with an inhaler.

Like many of you, I am a rheuma­tologist. And like you, I see some patients more often their own primary care provider. This is so often the case that I have gradually devolved into their backup, all-purpose doctor. I am the doc they notify when they get hospitalized for pneumonia or if they’re trying to decide whether to go ahead with the hip replacement they were told they need.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

From the patient’s perspective, I can understand the confusion. It must be difficult for them to understand why I seem keenly interested in some problems, but not others. After all, because I am the physician ordering the urinalysis, I must be the right doctor to approach about their urinary tract infection or their kidney stones.

eamesBot / shutterstock.com

EAMESBOT / shutterstock.com

Thus, I found myself trying to figure out why my patient was short of breath. In retrospect, the complaint was not new. In my defense, when a patient meets you because of digital ischemia caused by a medium-vessel vasculitis, his ability to run up a flight of stairs seems a little less interesting. Over the years, however, as his rheumatic disease improved, dyspnea gradually worked its way up his problem list until it was the only issue left.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

He knew what the problem was—for years, he was under the care of a pulmonologist for his chronic obstructive pulmonary disease. The diagnosis was well earned, after many years of smoking in a previous era, when smoking was encouraged. Honestly, his condition had not changed much: diminished air exchange, a faint wheeze at the end. I had just never thought of it as my problem to fix.

When he started telling me about scouring the shelves of his local pharmacy for Primatene Mist, an inhaled form of epinephrine that was taken off the market in 2011, I knew I had to step in, at least temporarily. I gave him a prescription for a few inhalers, extracted from him a promise to find a new lung doctor and sent him off. My good deed for the day.

I am not a conspiracist. I don’t believe a dark state is controlling the government. … I’m pretty sure that wasn’t Elvis who was spotted in the Nashville Publix parking lot. That said, I find it difficult to look at the price of generic drugs & not wonder whether the conspiracists may be onto something.

Or so I thought. When he returned for his routine follow-up appointment, I was not surprised to learn that he had not yet seen a pulmonologist—I knew it might take a few tries to make that happen. I was surprised, however, to learn that he had picked up only one of the two inhalers I had prescribed. Generic albuterol was cheap, and he was pleased to inform me that it seemed to be helping. The other inhaler was not generic and not cheap. He learned the prescription would have cost him $100 out of pocket, so he declined to pick up the drug. Perhaps not being able to breathe was not so bad, after all.

Generic Drugs 101

The U.S. Food and Drug Administration (FDA) defines a generic drug as “a medication created to be the same as an already marketed brand-name drug in dosage form, safety, strength, route of administration, quality, performance, characteristics and intended use.”1 The generic drug does not have to be completely identical to the original drug, but it does have to demonstrate bioequivalence, meaning that a patient should be able to take the brand-name drug one day and its generic counterpart the next and not notice a difference in effect.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:generic competitiongeneric drug makersnot-for-profit generic drugmaker

Related Articles

    Mark Cuban: Mixing Up the Pharmaceutical Landscape

    April 7, 2023

    The Mark Cuban Cost Plus Drug Co. (CPD) launched in January 2022 to distribute and home deliver prescribed generic medications to consumers. The Texas-based business seeks to reduce the prices of generic drugs by leapfrogging financial negotiators and going straight to drug companies for supply, according to a news release.1 “It’s crazy that medications are…

    Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment

    June 14, 2017

    While members of Congress debate healthcare legislation, rheumatologists say many of their patients struggle to afford everything from generic drugs to insurance copayments for physical therapy. “It’s a mess. The cost of prescriptions and the rationale for those rising costs in the U.S. right now—it’s just a mess,” says James R. O’Dell, MD, Stokes-Shackleford Professor of…

    The Birth and Growth of Biotechnology, and the Impact of Biologic Drugs on Rheumatology

    June 15, 2017

    Here’s a trivia question: Where were the big ideas for the field of biotechnology first discussed? Answer: At a since-demolished delicatessen in Waikiki Beach, Hawaii. Go figure. The year was 1972, and Stanley Cohen, MD, professor of medicine at Stanford University in Palo Alto, Calif., and Herbert Boyer, PhD, a former professor and biochemist at the…

    Psoriatic Arthritis Drugs at a Glance, 2023

    April 21, 2023

    Biosimilars have become a therapeutic turning point for many patients who are living with rheumatic illnesses. Psoriatic arthritis (PsA) is a complex, multi-faceted chronic inflammatory musculoskeletal and skin disease where the treatment has changed considerably over the past few years. Psoriatic arthritis has an impact on about 30% of people with psoriasis.1 In 2019, the…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences